Goldline Pharmaceutical Ltd.

As of March 31, 2025, Goldline Pharmaceutical Ltd. has 9.90M shares outstanding.

As of March 31, 2025, Goldline Pharmaceutical Ltd. maintains a current ratio of 1.98, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.58, indicating elevated leverage, while an interest coverage ratio of 3.28 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2025, Goldline Pharmaceutical Ltd. posted a return on equity (ROE) of 31.11, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 19.96 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.52, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 20.76, useful for judging operating efficiency across full business cycles. The company generates approximately 2.83M in revenue per employee across its workforce of 99.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.51 indicates how many times Goldline Pharmaceutical Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2025, Goldline Pharmaceutical Ltd. recorded 10.24M in income tax expense. That works out to an effective tax rate of 26.54, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 38.58M, leaving 28.34M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 21, 2026.

Over the twelve months ended March 31, 2025, Goldline Pharmaceutical Ltd. generated 280.56M in revenue and converted that into 28.34M in net income, yielding earnings per share of 2.86. EBITDA reached 60.56M, while operating income came in at 58.97M.

As of March 31, 2025, Goldline Pharmaceutical Ltd. holds 12.40M in cash and equivalents against 110.34M in total debt, resulting in a net debt position of 97.95M. Total book value stands at 103.53M, with working capital of 115.85M providing operational flexibility.

Goldline Pharmaceutical Ltd. produced 23.21M in operating cash flow over the twelve months ended March 31, 2025. After subtracting -2.07M in capital expenditures, free cash flow totaled 21.14M - equivalent to 2.14 per share.

Over the twelve months ended March 31, 2025, Goldline Pharmaceutical Ltd. posted a gross margin of 61.50, reflecting its pricing power and cost economics. The operating margin of 21.02 and net profit margin of 10.10 provide insight into operational efficiency.

Over the twelve months ended March 31, 2025, Goldline Pharmaceutical Ltd. paid dividends of 0.22 per share. The dividend payout ratio of 7.58 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.